Filing Flows › Foghorn Therapeutics (FHTX) › Q2 2026 › vs Q1 2026
Foghorn Therapeutics (FHTX) Q2 2026 vs Q1 2026 (quarter over quarter)
Foghorn Therapeutics's revenue rose $12.8M (+392%) from $3.3M in Q1 2026 to $16.1M in Q2 2026.
Foghorn Therapeutics, Q2 2026: revenue $16.1M (+113% year over year), operating margin -54.8%, net loss $7.2M, operating cash flow −$17.8M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $16.1M | $3.3M | $12.8M | +392% |
| Other income, net | $1.6M | $1.7M | −$84K | -5% |
| Net loss | $7.2M | $19.9M | −$12.7M | -64% |
| Costs & expenses | $24.9M | $24.8M | $37K | +0.1% |
| Operating costs | $24.9M | $24.8M | $37K | +0.1% |
| Research & development | $18.5M | $18.3M | $264K | +1% |
| General & admin | $6.4M | $6.6M | −$227K | -3% |
| Operating cash sources | $20.6M | $27.9M | −$7.3M | -26% |
| Depreciation & amortization | $200K | $238K | −$38K | -16% |
| Share-based compensation | $2.5M | $2.4M | $167K | +7% |
| Cash used in operations | $17.8M | $25.3M | −$7.4M | -29% |
| Net loss absorbed | $7.2M | $19.9M | −$12.7M | -64% |
| Working capital & other | $13.4M | $8.0M | $5.4M | +67% |
Questions
How much did Foghorn Therapeutics's revenue grow quarter over quarter in Q2 2026?
Foghorn Therapeutics's revenue rose $12.8M (+392%) from $3.3M in Q1 2026 to $16.1M in Q2 2026.